Skip to main content
Caplight Logo









SynDevRx

SynDevRx

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://syndevrx.com/

Last Round

Series C

Dec 22, 2025

Total Funding Raised

$31.33M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

SynDevRx is a clinical-stage biotechnology company that develops treatments for cancers sensitive to metabolic hormones.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoverymetabo-oncologyclinical trialsMetAP2 inhibitorcachexia treatmentsmall-molecule drugcancer metabolismbiotechevexomostatSDX-7320drug developmentmetabolic diseasetherapeutic candidateoncology research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SynDevRx Comparables

Compare SynDevRx with similar companies based on industry and business-model similarity.

SynDevRx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Partex
80%
Kalohexis
79%
Actimed Therapeutics
78%

SynDevRx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CDec 22, 2025
GrantJan 9, 2025
VC RoundNov 4, 2024
GrantAug 31, 2022
Series BJan 25, 2022
Series B
Jan 9, 2020

Key People

Founding team and executive leadership

James Shanahan

Co-Founder, Chief Business Officer

Founding Team

Brad Carver

Co-founder, President, CEO and Chairman

Founding Team

David Neafus

CFO

Executive Team

SynDevRx Investors

Notable investors and investment history

SynDevRx investors
InvestorRounds
U.S. Department of WarGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 190% MoM.

  • Dec 22, 2025

    Raised $6.4M in Series C funding.

SynDevRx Filings

Explore SEC and related filing metadata, where available.

SynDevRx filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SynDevRx's valuation, stock price, and market status.

Is SynDevRx a public or private company?

SynDevRx is a private company.

What is the current stock price of SynDevRx?

SynDevRx is a private company with no public stock price. No recent secondary market data is available.

How much is SynDevRx worth (valuation)?

Valuation information for SynDevRx is not publicly available.

Can I buy SynDevRx stock?

SynDevRx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SynDevRx's last funding round?

SynDevRx's most recent funding round was Series C on October 10, 2024.

Who are the main investors in SynDevRx?

Investor information for SynDevRx is not publicly disclosed.

Will SynDevRx IPO soon?

No public IPO plans have been announced for SynDevRx.

How can I track SynDevRx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SynDevRx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range5
Year Founded2007
Last FundingDec 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?